Pfizer Inc. (NYSE:PFE) is among the Top 15 Lowest P/E Ratios of the S&P 500 in 2025. On December 1, Citi resumed coverage of the stock with a Neutral rating and a $26 share price target.
In a research note to investors, the analyst shared a mixed outlook for the stock. Citi noted the company’s operational gains and a clear policy environment, while adding that challenges from the Medicare Part D program offset these.
The adjustment follows Guggenheim’s recent update on Pfizer Inc. on November 26, in which it lifted its price target on the stock to $35 from $33, while keeping a Buy rating.
Guggenheim cited Pfizer’s acquisition of Metsera as the reason behind the revision, saying the move was likely to drive momentum for the company in the market for obesity drugs.
As of the close of business on December 5, around 60% of the 26 Wall Street analysts with recommendations on Pfizer have a Hold rating for the stock. The pharmaceuticals company has a one-year average share price target of $29.04, representing an upside potential of 12%.
Pfizer Inc. develops, sells, and distributes a wide range of vaccines and drugs worldwide. The stock is down 2% year-to-date.
READ NEXT: 10 Best Drone Stocks to Buy Right Now and 8 Best Small-Cap Defense Stocks to Buy Right Now
Hedge Fund Resource Center